Evaluating Neurotherapeutic Potential of Naringenin by True Experiments: Insights into In-Vivo Psychiatry Care Models

Background: The brain function and development are impaired when psychiatric disorders cause neuroinflammation and neurotrophic dysregulation. This study aimed to evaluate the Naringenin's neurotherapeutic potential utilizing controlled in vivo trials, with an emphasis on its function in controlling neuroinflammation and restoring neurotrophic balance in a psychiatric care model. Methods: The in vivo experimental research took place during four months, from April 2021 to August 2021, utilizing 20 healthy male rats, aged eight weeks. Experiments were performed on animals at the Animal House, and biochemical analyses were carried out at SMDC Lahore and LUMHS Jamshoro. The subjects were divided into five groups: Group I (control) and Groups II–V, which received 250 mg/kg/day of propionic acid (PPA) to induce neuroinflammation that resembled psychiatric disorders. Naringenin was administered to Groups III–V at escalating doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg after PPA was induced for four weeks. The ELISA testing system measured Nerve Growth Factor (NGF) serum concentrations, and the data were analyzed with one-way ANOVA followed by Tukey post hoc comparisons between all samples. Data analysis was conducted using SPSS Version 21. Results: The Naringenin treatment resulted in stepwise elevation in NGF levels across various doses, and the 200 mg/kg dosage delivered nearly normal levels of NGF. The NGF measurements (pg/mL) were as follows: Group I – 11.5 ± 0.5, Group II – 4.0 ± 0.5, Group III – 9.2 ± 0.5, Group IV – 7.6 ± 0.5, and Group V – 9.7 ± 0.5. The therapeutic function of Naringenin to counteract neurotrophic deficits caused by inflammation finds support from these observed improvements. Conclusion: The in vivo psychiatric care models reveal the neurotherapeutic potential of naringenin, because it fights neuroinflammation and restores NGF levels to normal.